Johnson & Johnson Just Proved The Bears Wrong Again

2025-04-24 07:46:40 ET

Summary

• Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga.
• It beat the consensus estimates again by a wide margin, thanks to its leading positions in the oncology and immunology market.
• So, sales of Tremfya amounted to $956 million, and Darzalex reached $3.24 billion in the first quarter of 2025, an increase of 18.3% and 20.2% year-on-year, respectively.
• Johnson & Johnson also reached a significant R&D milestone in mid-April when icotrokinra, an oral IL-23 pathway inhibitor, showed stunning results in the treatment of plaque psoriasis.
• In this article, you will learn about extra reasons why I continue to cover it with a 'Buy' rating.

On April 15 , Johnson & Johnson (JNJ) reported financial results for the first three months of 2025 that again beat my and Wall Street analysts' expectations by strong margins, coming as a breath of fresh air after yet another failed attempt to settle talc-related lawsuits .

The New Brunswick-based company's revenue reached $21.89 billion, and its non-GAAP EPS was $2.77, up 2.39% and 2.2% year-on-year, respectively, thanks to sales growth in both of its business segments, namely MedTech and Innovative Medicine....

Read the full article on Seeking Alpha

For further details see: